Recent Company News

• 07:03 AM ET May 01, 2025
  

  PureTech Health to present results from Phase 2B ELEVATE IPF trial of LYT-100 at the ATS International Conf (127.0000p, +4)

• 02:20 AM ET Apr 30, 2025
  

  PureTech Health reports FY net income $53.5M vs FactSet ($183.8M) [1 est] (125.8000p, 0)

• 04:26 AM ET Apr 08, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 04:19 PM ET Apr 22, 2025
  

  Bristol Myers Squibb announces topline results from Phase 3 ARISE trial evaluating Cobenfy as adjunctive treatment to atypical antipsychotics in adults with schizophrenia ($49.82, 0.00)

• 10:25 AM ET Apr 09, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (697 total)

• 03:55 AM ET Apr 09, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (98 total)

• 10:10 AM ET Apr 08, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (30 total)

• 11:35 AM ET Apr 07, 2025
  

  PureTech Health confirms discussions regarding a possible cash offer by Nordic Capital Epsilon SCA, SICAV-RAIF for the entire share capital of the company (128.8000p, 0)